Skip to main content
. 2019 Jan 25;17(3):3071–3076. doi: 10.3892/ol.2019.9972

Figure 3.

Figure 3.

The PFS and OS rates of patients with non-small cell lung cancer with anaplastic lymphoma kinase fusion. Kaplan-Meier survival analysis of patients with p-PDGFRA-positive vs. -negative tumor samples. (A) No significant difference was observed between the PFS time of patients with detectable p-PDGFRA expression compared with those without (log-rank test, P=0.6). (B) No significant difference was observed between the OS time of patients with detectable p-PDGFRA expression compared with those without (log-rank test, P=0.6). PFS, progression-free survival; OS, overall survival; p-PDGFRA, phosphorylated platelet-derived growth factor receptor α.